Blog Archives

Anti-infective pilot entries

GtoPdb has been traditionally focused on the pharmacology associated with human diseases (i.e. we have not been funded to cover anti-infectives).  In 2017 we have been exploring possible funding opportunities to extend into  expert curation of anti-infectives, particularly in the

Posted in Uncategorized

Reference Citations in BJP and NAR metrics

Introduction Like other database resources, we collate measures of impact for various uses. These include our own internal bi-annual IUPHAR/GtoPdb review meetings, documenting outputs of past grants and applications for new ones. While there is a widening choice of these

Posted in Publications, Uncategorized

GtoPdb Ligands in PubChem

GtoPdb and  its precursor IUPHAR-DB have been capturing the structures of pharmacologically relevant ligands since 2005.  The fig.1. snapshot below  shows the approved drug section of our eight-category ligand classification As an active collaboration with the  PubChem team, we have

Posted in Uncategorized

Why Data Citation Is a Computational Problem

By Peter Buneman The database development team encouraged me to write this off-topic blog on data citation, as it may be of interest to people involved with the IUPHAR/BPS Guide to Pharmacology (GtoPdb). It must be almost ten years ago

Posted in Uncategorized

Recent DrugBank Changes

The DrugBank database has just announced (09 May 2016) more restrictive access conditions including user registration. Not unexpectedly, this has prompted discussion on Twitter and elsewhere (e.g. ThinkLab. including some from the DrugBank team).  We enjoy long-standing contacts with the

Posted in Uncategorized

Assessment of GtoPdb in-links

A valuable aspect of biological databases in general and the IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb) in particular, are out-links to and in-links from, other relevant resources.

Tagged with: , ,
Posted in Uncategorized

Curating PDB links between proteins and 3D chemical structures

We know users find our curated PDB links of high value, particularly where the ligand co-crystalised within the target protein is an activity-mapped approved drug, clinical candidate or key metabolite. The comparative SAR insights these can provide are substantial, especially

Posted in Uncategorized